trending Market Intelligence /marketintelligence/en/news-insights/trending/Qq8iYYhIPpa6nnK2xtAK-A2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Mylan receives US FDA approval for generic Copaxone

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Mylan receives US FDA approval for generic Copaxone

Mylan NV said the U.S. Food and Drug Administration approved its generic version of Teva Pharmaceutical Industries Ltd.'s Copaxone to treat relapsing forms of multiple sclerosis.

The FDA approved Mylan's abbreviated new drug applications for glatiramer acetate injection in 40 milligrams/milliliter and 20 mg/milliliter doses. Additionally, the company may be eligible for 180 days of generic drug exclusivity, though no formal decision was disclosed.

FDA Commissioner Scott Gottlieb recently said in a blog post that he wants to bring more competition to older complex medicines, such as drug-device combinations comprising a small-molecule chemical agent that requires the use of a metered-dose inhaler, like those for asthma, or certain injectable drugs, such as Copaxone.